Legend Biotech
LEGN
211 hedge funds and large institutions have $3.23B invested in Legend Biotech in 2024 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 94 increasing their positions, 52 reducing their positions, and 35 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 52
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
11% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 35
1.89% more ownership
Funds ownership: 25.04% → 26.94% (+1.9%)
1% more funds holding
Funds holding: 208 → 211 (+3)
27% less capital invested
Capital invested by funds: $4.44B → $3.23B (-$1.21B)
43% less call options, than puts
Call options by funds: $8.76M | Put options by funds: $15.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$145M |
| 2 |
Goldman Sachs
New York
|
+$84.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$65.8M |
| 4 |
DM
Deerfield Management
New York
|
+$64.3M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$59.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$202M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$180M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$47.9M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$27M |
| 5 |
CCM
Cutter Capital Management
New York
|
-$15.9M |
LEGN Hedge Fund Activity: Q4 2024 in Review
211 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q4 2024, worth a combined $3.23B — down 27% from $4.44B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new LEGN positions and 35 closed out — a net gain of 4 holders — while 94 added to existing stakes and 52 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $145M. The largest seller was Fidelity Investments, cutting an estimated $202M.
- 211 institutional investors held Legend Biotech (LEGN) as of Q4 2024, up from 208 in Q3 2024.
- Funds reported $3.23B of Legend Biotech stock for Q4 2024, down 27% quarter-over-quarter.
- 39 funds opened new Legend Biotech positions in Q4 2024 and 35 closed out, a net change of +4 holders.
- The largest Legend Biotech buyer in Q4 2024 was Suvretta Capital Management, an estimated $145M added.
- The largest Legend Biotech seller in Q4 2024 was Fidelity Investments, an estimated $202M sold.
Based on aggregated 13F filings for Q4 2024.